Anti-Human ApoE4 (Clone 4E4) – Purified No Carrier Protein

Anti-Human ApoE4 (Clone 4E4) – Purified No Carrier Protein

Product No.: A442

- -
- -
Clone
4E4
Target
ApoE4
Formats AvailableView All
Product Type
Hybridoma Monoclonal Antibody
Alternate Names
Apolipoprotein E4
Isotype
Mouse IgG1 κ
Applications
ELISA
,
IF
,
IHC
,
IP
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Mouse
Immunogen
Synthetic peptide made to an internal region of human ApoE4
Product Concentration
0.5 mg/ml
Formulation
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
State of Matter
Liquid
Storage and Handling
This purified antibody is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Shipping
2-8°C Wet Ice
Additional Applications Reported In Literature ?
ELISA,
IHC,
IP,
WB,
IF
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
4E4 activity is specific to ApoE4, recognizing an internal domain present exclusively in the ApoE4 isoform.
Background
Apolipoprotein E (ApoE) is a glycoprotein involved in lipid metabolism encoded by three isoforms, ApoE2, ApoE3, and ApoE4, which differ at residues 112 and 158 (E2: C112, C158; E3: C112, R158; E4: R112, R158)1. Carriers of the ApoE4 isoform are more likely to develop Alzheimer’s Disease (AD), with cognitive changes also occurring earlier2. ApoE4 has been implicated in increased amyloid β deposition, a key marker of AD, and has an effect on lipid metabolism, inflammation, phosphorylation of tau protein, and mitochondrial function. ApoE4 is also a risk factor for cerebral amyloid angiopathy, dementia with Lewy bodies, tauopathy, cerebrovascular disease, multiple sclerosis, vascular dementia, and is related to poor outcome following head injury. In contrast, ApoE4 is protective for age-related macular degeneration. Lower concentrations of ApoE are found in ApoE4 carriers. However, it is unknown how the amount of ApoE4 present intersects with its functional activity to increase risk of disease. Anti-ApoE4 therapies that aim to mitigate the pathological effects of ApoE4 and inhibit amyloid accumulation are under study.
Antigen Distribution
ApoE is produced differentially in the central nervous system by astrocytes and microglia as well as peripherally by the liver and macrophages. ApoE does not cross the blood–brain barrier.

Antigen Details

NCBI Gene Bank ID
Research Area
Cell Biology
.
Neuroscience
.
IVD Raw Material

References & Citations

1. Veiga S, Rodríguez-Martín A, Garcia-Ribas G, et al. Sci Rep. 10(1):2138. 2020.
2. Safieh M, Korczyn AD, Michaelson DM. BMC Med. 17(1):64. 2019.
3. Calero O, García-Albert L, Rodríguez-Martín A, et al. Sci Rep. 8(1):5969. 2018.
4. Kotredes KP, Oblak A, Pandey RS, et al. Front Aging Neurosci. 13:735524. 2021.
5. Qi G, Mi Y, Shi X, et al. Cell Rep. 34(1):108572. 2021.
6. Lennol MP, Sánchez-Domínguez I, Cuchillo-Ibañez I, et al. Alzheimers Res Ther. 14(1):161. 2022.
7. Sepulveda J, Luo N, Nelson M, et al. J Neurochem. 163(3):247-259. 2022.
8. Foley KE, Hewes AA, Garceau DT, et al. Front Aging Neurosci. 14:838436. 2022.
9. Zhang M, Gong W, Zhang D, et al. Cell Death Dis. 13(4):406. 2022.
Indirect Elisa Protocol
IF
IHC
Immunoprecipitation Protocol
General Western Blot Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.